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Abstract: Known as naturally occurring biologically active compounds, flavokawain A and 
B are the leading chalcones that possess anticancer properties. Another flavokawain derivative, 
(E)-1-(2′-Hydroxy-4′,6′-dimethoxyphenyl)-3-(4-methylthio)phenyl)prop-2-ene-1-one (FLS) 
was characterized with 1H-nuclear magnetic resonance, electron-impact mas spectrometry, 
infrared spectroscopy, and ultraviolet (1H NMR, EI-MS, IR, and UV) spectroscopic techniques. 
FLS cytotoxic efficacy against human cancer cells (MCF-7, MDA-MB-231, and MCF-10A) 
resulted in the reduction of IC
50
 values in a time- and dose-dependent mode with high specificity 
on MCF-7 (IC
50
 of 36 μM at 48 hours) against normal breast cell MCF-10A (no IC
50
 detected 
up to 180 μM at 72 hours). Light, scanning electron, and fluorescent microscopic analysis of 
MCF-7 cells treated with 36 μM of FLS displayed cell shrinkage, apoptotic body, and DNA 
fragmentation. Additionally, induction of G2/M cell arrest within 24 hours and apoptosis at 
subsequent time points was discovered via flow cytometry analysis. The roles of PLK-1, Wee-1, 
and phosphorylation of CDC-2 in G2/M arrest and proapoptotic factors (Bax, caspase 9, and 
p53) in promotion of apoptosis of FLS against MCF-7 cells were discovered using fluorometric, 
quantitative real-time polymerase chain reaction, and Western blot analysis. Interestingly, the 
presence of SCH
3
 (thiomethyl group) on ring B structure contributed to the selective cytotoxic-
ity against MCF-7 cells compared to other chalcones, flavokawain A and B. Overall, our data 
suggest potential therapeutic value for flavokawain derivative FLS to be further developed as 
a new anticancer drug.
Keywords: (E)-1-(2′-Hydroxy-4′,6′-dimethoxyphenyl)-3-(4-methylthio)phenyl)prop-2-ene-1-
one (FLS), MCF-7, G2/M arrest, apoptosis, cell cycle, PLK-1, p53, caspase
Introduction
Breast cancer is the leading cause of cancer death in females worldwide, accounting 
for ~25% (1.68 million cases) of the total new cancer cases and ~14% (521,900 deaths) 
of the total cancer deaths in 2012.1,2 Among the various types of cancer, breast cancer 
is the most frequently diagnosed and the most common cancer that affects Malaysian 
women from all ethnicities.3 According to recent reports, an estimated 232,670 
new cases of breast cancer have been expected and diagnosed among women and 
about 2,360 new cases in men in the US during 2014.4,5 Although numerous efforts 
have been made to decrease the mortality rate of breast cancer,6 to-date, no ultimate 
chemotherapeutic drug is available to overcome this disease. Thus, effort in search-
ing alternative or better candidates of antibreast cancer compound from natural phy-
tochemical or synthetic chemistry is still ongoing.7
A number of studies have reported the broad spectrum bioactivities of chalcones 
including antioxidant, cytotoxic, anti-inflammation, antihistaminic, and antimicrobial 
effects.8 Flavokawains (either A, B, or C) are among the well-studied chalcones that 
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were extracted from Piper methysticum. Flavokawain A 
(FLA) constituted as the highest amount of flavokawain 
found in kava extract, while flavokawain B (FLB) is the most 
well studied flavokawain. Both flavokawain possess various 
level of cytotoxicity against several cancer cell line including 
colon, bladder, and breast.9–12 An ideal cytotoxic compound 
should possess good selectivity against the targeted cancer 
cell while inducing limited or no toxicity against normal 
cell.9 Comparing the cytotoxic effect of FLA and FLB, 
these two compounds were recorded with different degrees 
of in vitro cytotoxicity against estrogen-dependent MCF-7 
(FLA: ~25 μM; FLB: ~33 μM) and estrogen-independent 
MDA-MB-231 (FLA: ~17 μM; FLB: ~12 μM) breast cancer 
cell lines. However, both flavokawains also exhibited cyto-
toxicity on normal MCF-10A (FLA: ~95 μM; FLB: ~45 μM) 
breast cell line.9,10 Synthesis of bioactive compounds allows 
the possibility of modifying the lead compound for better effi-
cacy and desired cytotoxic action. For example, Badisa et al7 
have shown that synthetic piperidinyl-diethylstilbestrol and 
pyrrolidinyl-diethylstilbestrol possessed better selectivity 
against breast cancer MCF-7 cell than normal breast MCF-
10A cell. In this investigation, a flavokawain derivative, 
(E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-(methylthio)
phenyl)prop-en-1-one (FLS) was synthesized via a Claisen–
Schmidt condensation reaction. Thus, the aim of this study 
was to compare the selectivity of flavokawain derivative 
FLS on breast cancer and normal cell lines. In addition, the 
regulation of cell cycle and apoptotic inducing effect of FLS 
against MCF-7 were also observed.
Materials and methods
synthesis of Fls
FLS was synthesized via a Claisen–Schmidt condensation reac-
tion. Acetophenone, 4,6-dimethoxy-2′-hydroxyacetophenone 
3.0 g (9.0 mmol) and 4-(methylthio)benzaldehyde (1.4 mL, 
10 mmol) were dissolved in methanol. A 40% water solu-
tion of potassium hydroxide 5.0 g and 50 mL methanol was 
mixed in a 500 mL round bottle flask and left for 15 minutes 
at room temperature. The crude product was transferred into 
separating funnel (500 mL) and then added with 200 mL dis-
tilled water. The mixture was then acidified with the addition 
of 2–3 mL hydrochloride. The product was extracted with 
100 mL ethyl acetate. The organic layer was then successively 
washed with brine and dried over anhydrous sodium sulfate. 
The crude product was finally purified by flash column chro-
matography with ethyl acetate and hexane (5:5) as eluants and 
recrystallized in ethyl acetate and drops of MeOH.
MTT cell viability assay
MCF-7, MDA-MB-231, and MCF-10A cells (American 
Type Culture Collection [ATCC], Manassas, VA, USA) 
were seeded overnight in 96-well plates at a concentration 
of 0.8×105 cells/mL at 37°C CO
2
 incubator in Roswell Park 
Memorial Institute medium-1640, Dulbecco’s Modified 
Eagle’s Medium (DMEM), and DMEM-F12 supplemented 
with hydrocortisone (0.5 μg/mL), insulin (10 μg/mL), human 
epidermal growth factor (20 ng/mL) (Sigma-Aldrich Co., 
St Louis, MO, USA) medium, respectively. Then, respective 
cells were treated with FLS (ranging between 180 and 3 μM) 
for 24, 48, and 72 hours. MTT solution (5 mg/mL) was added 
to all wells 3 hours before end of incubation time. Absorbance 
was read at wavelength of 570 nm (BioTek Instruments, 
Winooski, VT, USA).13 Percentage viability of the tested cell 
line was calculated using the following formula:
 
Cell
viability
Absorbance sample
Absorbance untreated con(%)
=
trol
×100%
 
IC
50
 value indicating concentration that inhibited 50% of 
the tested cell lines was obtained from the graph plotted with 
percentage of cell viability against concentration of FLS.
McF-7 cell treatment
Based on the MTT assay (Table 1), reduction in IC
50
 values of 
FLS was observed after treatment at 24–72 hours on MCF-7 
Table 1 comparison values of ic50 of Fls, Fla, and FlB in McF-7, MDa-MB-231 and McF-10a cells
Cell lines FLS (µM) FLA (µM)9 FLB (µM) (Abu et al)10
24 hours 48 hours 72 hours 72 hours 72 hours
McF-7 40.90±4.50 36.36±3.10 33.30±2.50 25.13±3.00 33.76±1.35
MDa-MB-231 63.64±3.80 51.52±4.20 48.48±3.40 17.49±1.50 12.31±1.22
McF-10a .180 .180 .180 .100 45
selective index of McF-10a/McF-7 .4.40 .4.95 .5.41 3.98 1.33
selective index of McF-10a/MDa .2.83 .3.49 .3.71 5.72 3.66
Notes: adapted from abu n, akhtar Mn, Yeap sK, et al. Flavokawain a induces apoptosis in McF-7 and MDa-MB231 and inhibits the metastatic process in vitro. PLoS One. 
2014;9:e105244.9 adapted from abu n, akhtar M, Yeap s, et al. Flavokawain B induced cytotoxic ity in two breast cancer cell lines, McF-7 and MDa-MB231 and inhibited 
the metastatic potential of MDa-MB231 via the regula tion of several tyrosine kinases in vitro. BMC Complem Altern M. 2016;16:86.10
Abbreviations: Fls, (e)-1-(2′-hydroxy-4′,6′-dimethoxyphenyl)-3-(4-methylthio)phenyl)prop-2-ene-1-one; FLA, flavokawain A; FLB, flavokawain B.
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cytotoxicity of Fls
verifying that FLS effect is time- and dose-dependent. To 
standardize the treatment, one concentration of FLS (36 μM) 
was used for the remaining assays. MCF-7 cell was seeded 
at 0.8×105 cells/mL overnight in 6-well plate. After reaching 
80%–90% confluence, the cell was treated with 36 μM (IC
50
 
at 48 hours) of FLS for 24, 48, and 72 hours. Untreated control 
was prepared simultaneously. After 24, 48, or 72 hours of incu-
bation, cell was harvested using TrypLE (Thermo Fisher Sci-
entific, Waltham, MA, USA), washed with phosphate-buffered 
saline and subjected to the subsequent assays.
light and scanning electron microscopic 
examination
Cell was subjected to microscopic examination using inverted 
light microscope (Nikon Corporation, Tokyo, Japan) and 
scanning electron microscope (SEM; JEOL, Tokyo, Japan) 
after 72 hours of treatment. Prior to SEM observation, cell 
was seeded on poly-l-lysine coated round coverslips in 
a 6-well plate. After 72 hours, untreated control and FLS 
treated MCF-7 cell were fixed in 4% glutaraldehyde, washed 
with 0.1 M sodium cocodylate buffer, fixed with 1% osmium 
tetroxide and underwent series of dehydration in acetone and 
dried using CO
2
. Then, the samples were mounted onto the 
stubbing, coated with gold in sputter and viewed under JEOL 
SEM under the 15 kV setting.
acridine orange/propidium iodide dual 
staining
Harvested cell was stained with 10 μg/mL of acridine orange 
and propidium iodide (PI) each. The morphology of cell was 
observed under fluorescent microscope (Nikon) with combi-
nation of excitation filter (450–490 nm) and long pass filter 
(520 nm). Random scoring of 200 cells for both untreated and 
FLS-treated MCF-7 was taken to determine the percentage of 
viable (green intact cell), apoptotic (green cell with condensed 
or fragmented nucleus), and necrotic (red cell) cells.
cell cycle analysis
Cell cycle progression was evaluated using BD Cycletest Plus 
kit and subjected to BD FACS Calibur flow cytometer (BD, 
Franklin Lakes, NJ, USA) analysis. In brief, harvested cell 
was incubated with 250 μL of trypsin buffer for 10 minutes 
followed by 200 μL of trypsin inhibitor with RNase buffer. 
The samples were finally stained with 200 μL of PI solution 
and analyzed.
annexin V/Pi apoptosis study
Apoptosis of cell was evaluated using BD Annexin 
V-fluorescein isothiocyanate (FITC)/PI apoptosis detection 
kit. In brief, harvested cell was washed and added with 
100 μL of 1× binding buffer. The cell was then stained with 
5 μL of Annexin V-FITC and 5 μL of PI solution, incubated 
for 15 minutes and diluted with 400 μL of 1× binding buf-
fer. All samples were analyzed with BD FACS Calibur flow 
cytometer (Becton Dickinson).
Quantitative reverse transcription real-
time Pcr assay
RNA was extracted from cell using RNeasy mini plus 
kit (Qiagen NV, Venlo, the Netherlands). The purity and 
concentration of the isolated RNA were quantified prior to 
DNA conversion using iScript cDNA synthesis kit (Bio-Rad 
Laboratories Inc., Hercules, CA, USA). Expression of polo-
like kinase 1 (PLK1), WEE1 G2 checkpoint kinase (WEE-1), 
c-Jun proto-oncogene (c-Jun), Glucose transporter (GLUT) 
were quantified by quantitative real-time PCR (qRT-PCR) 
using SYBR select master mix (Thermo Fisher Scientific) 
on iQ-5 real-time polymerase chain reaction (PCR) machine 
(Bio-Rad) with normalization to three housekeeping genes, 
β-actin, 18srRNA, and GAPDH. All primers are listed in 
Table 2. PCR condition for this experiment was 1 cycle 
of 50°C/2 minutes for Uracil-DNA glycosylase (UDG) 
activation; 1 cycle of 95°C/2 minutes for DNA polymerase 
Table 2 The accession number and sequence of the primers used in the quantitative real-time Pcr assay
Accession number Gene Sequence
nM_001101.3 ACTB F: 5′-agagcTacgagcTgccTgac-3′
r: 5′-agcacTgTgTTggcgTacag-3′
nM_002046.4 GAPDH F: 5-ggaTTTggTcgTaTTgggc-3
r: 5-TggaagaTggTgaTgggaTT-3
hQ387008.1 18S rRNA F: 5-gTaacccgTTgaaccccaTT-3
r: 5-ccaTccaaTcggTagTagcg-3
nM_005030.3 PLK1 F: 5-ccTgcaccgaaaccgagTTaT-3
r: 5-ccgTcaTaTTcgacTTTggTTgc-3
nM_001143976.1 WEE-1 F: 5-gggaaTTTgaTgTgcgacag-3
r: 5-cTTcaagcTcaTaaTcacTggcT-3
nM_006516.2 GLUT1 F: 5-acaacacTggagTcaTcaaTgc-3
r: 5-ccacagagaaggagccaaTca-3
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
10
3.
53
.3
2.
15
0 
on
 0
3-
Fe
b-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1900
ali et al
activation; 40 cycles of 95°C 2 seconds for denature, 60°C for 
30 seconds for anneal and extend. Normalization of reference 
genes was carried out using geNorm algorithm.
Western blot analysis
Harvested cell was lysed with radioimmunoprecipitation 
assay (RIPA) buffer supplemented with phosphatase inhibitor 
cocktail (Hoffman-La Roche Ltd., Basel, Switzerland) prior 
to protein quantification using Bradford assay (Sigma-Aldrich 
Co.). Next, 100 μg of cell lysate was electrophoresed in 10% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) (Bio-Rad), transferred to nitrocellulose mem-
brane using Pierce Fast Semi-Dry Blotter (Pierce, Thermo 
Fisher Scientific, Waltham, MA, USA), blocked with 0.5% 
skimmed milk and incubated with primary antibodies (anti-
CDC2, anti-p-CDC2, anti-p53, anti-Bax, anti-Bcl-2, and anti-
β-actin at dilution 1:1,000) (Abcam, San Francisco, CA, USA) 
for 1 hour. Following that, membrane was washed, incubated 
with goat anti-rabbit immunoglobulin G (IgG) and haematoxy-
lin and eosin stain (H&E) conjugated to alkaline phosphatase 
(Abcam) in 1:5,000 dilution and developed under chemilu-
minescence condition (SuperSignal West Pico, Pierce) using 
ChemiDoc XRS (Bio-Rad). The bands, intensity was analyzed 
using Quantity One 1D analysis software (Bio-Rad).
caspase 9 and cytochrome c detection 
study
Extracted protein from previous Western blot analysis was also 
subjected to detection of caspase 9 and cytochrome c using 
CaspGLOW Red Active Caspase-9 staining kit (BioVision, 
Milpitas, CA, USA) and human cytochrome c platinum 
enzyme-linked immunosorbent assay (ELISA) (eBioscience 
Affymetrix, Santa Clara, CA, USA). The fluorescence inten-
sity in active caspase 9 was measured at Ex/Em =540/570 nm 
using microplatefluorometer (Thermo Scientific). On the other 
hand, absorbance for human cytochrome c was measured 
using ELISA plate reader at wavelength of 450 nm (BioTek 
Instruments). Fold change of caspase 9 and cytochrome c were 
calculated by dividing fluorescence intensity or absorbance of 
FLS treated MCF-7 with untreated control MCF-7.
statistical analysis
The data are presented as average of mean ± SE (standard 
error of the mean), one-way analysis of variance was used to 
assess differences between time point groups. Results were 
considered statistically significant when P,0.05.
The Ethical Committee for Research in Universiti Putra 
Malaysia, decided that ethical approval was unnecessary for 
using commercial human cell lines. 
Results
synthesis of Fls
FLS was the yellow flat crystals with 78.6% yield through 
the synthesis. IR (CHCl
3
): 1,642–1,644 (C=O), 1,550–1,568 
(C=C–C=O), 1,458–14,728 (C=C, Ar), and 1,200–1,100 
(C–O) cm−1. 1HNMR (CDCl
3
, 500 MHz): δ14.30 (chelated 
OH), 7.86 (IH, J=15.5 Hz, Hβ), 7.53 (d, 1H, J=15.5 Hz, 
Hα), 7.50 (br, d, 2H, H-2,6), 7.26 (m, 3H, H-3,4,5), 5.95 
(d, J=2.5 Hz, 1H, H-3′), 5.90 (d, 1H, J=2.5 Hz, H-5′), 3.90 
(s, 3H, OMe, C-6′), 3.82 (s, 3H, OMe, C-4′), 2.54 (s, 3H, 
S-CH
3
). Electron-Impact Mas Spectrometry has indicated 
that synthesised FLS has molecular weight of 330.32 with 
molecular formula C
18
H
18
O
4
S. Molecular structures of FLS, 
FLA, and FLB are shown in Figure 1.
+&2 2&+ 6&+
2+
)/6 )ODYRNDZDLQ$
)ODYRNDZDLQ%
2
$ %
+&2 2&+ 2&+
2+ 2
+&2 2&+
2+ 2
Figure 1 The molecular structures of FLS, flavokawain A and flavokawain B.
Abbreviation: Fls: (e)-1-(2′-hydroxy-4′,6′-dimethoxyphenyl)-3-(4-methylthio)phenyl)prop-2-ene-1-one.
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
10
3.
53
.3
2.
15
0 
on
 0
3-
Fe
b-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1901
cytotoxicity of Fls
Fls selectively reduced the viability of 
McF-7 cell
FLS provoked a time-dependent cytotoxicity against both 
MCF-7 and MDA-MB-231 cells with 50% reduction in 
a reducing concentration from 24 to 72 hours. The IC
50 
value of FLS on MDA-MB-231 was 1.5-fold higher than 
on MCF-7 indicating that FLS is more sensitive to MCF-7 
(IC
50
 ~33 μM) than to MDA-MB-231 (IC
50
 ~48.5 μM) 
(Table 1). On contrary, no cytotoxicity against normal breast 
cell MCF-10A can be detected up to 180 μM. Selective index 
(SI) was calculated based on the IC
50 
value of FLS on MCF-
10A comparing to MCF-7 or MDA-MB-231. FLS exhibited 
greater selectivity of MCF-7 (SI .5) cell than MDA-MB-231 
(SI .3) against MCF-10A.
Morphology observation of McF-7 
treated with Fls
Untreated MCF-7 cells were confluent with normal mor-
phology (Figure 2A). FLS (36 μM) reduced the cell num-
ber of MCF-7 and induced cell shrinkage after 72 hours 
of treatment. Also, detachment of cell was also observed 
(Figure 2B). Scanning electron micro scopy has provided a 
clearer comparison between ultrastructure of untreated and 
FLS treated MCF-7 after 72 hours of incubation. Untreated 
control MCF-7 was observed with normal cell morphology 
with extended structure and microvilli observed indicating 
the control cell was healthy and stably attached on the glass 
slide (Figure 2C). In contrast, morphological changes related 
to apoptosis including cell shrinkage, irregular surface, large 
hole, and apoptotic body were observed in the FLS treated 
MCF-7 (Figure 2D). In addition, apoptosis, necrosis, and via-
bility of MCF-7 cell treated with FLS were also investigated 
under fluorescent microscope after staining with acridine 
orange and PI. Viable cell was stained as green intact cell 
(Figure 2E). On the other hand, MCF-7 cell treated with FLS 
was observed with significant increase of apoptotic popula-
tion (P,0.05), which was marked by chromatin condensa-
tion, cell shrinkage and membrane blebbing (Figure 2F). 
Based on random scoring of ~200 cells, untreated control 
MCF-7 cell was recorded with .95% of viable population. 
Unlike control, FLS treatment induced ~26% of apoptosis 
and 14.5% of necrosis or late apoptosis after 72 hours of 
incubation (Figure 2G).
Fls induced g2/M cell cycle arrest 
followed by apoptosis on McF-7
Cell cycle progression of FLS (36 μM) treated MCF-7 was 
examined by flow cytometry PI staining assay. Result of 
cell cycle analysis is summarized in Figure 3. Significant 
(P,0.05) G2/M arrest was noticed after 24 hours of FLS 
treatment. Subsequently, 48 and 72 hours of FLS treatment 
were found with drastic increase of sub G
0
/G
1 
population 
on MCF-7 indicating the possibility of DNA fragmentation 
to happen. To confirm the apoptotic inducing effect of FLS 
on MCF-7 at 48 and 72 hours, Annexin V/PI apoptosis 
flow cytometry was done to evaluate the late and early 
apoptosis indicated by externalization of phosphatidyl-
serine with or without loss of membrane integrity (that 
allow PI to enter and stain the DNA), respectively. Based 
on the Annexin V/PI result, early apoptosis was noticed 
with constant increase from 9.18% to 36.72% from 24 to 
72 hours. Besides, 11.86% of late apoptosis was observed 
after 48 hours and further increased to 17.29% at 72 hours 
on FLS treated MCF-7 cell (Figure 3). These results indi-
cated that FLS treatment promoted G2/M cell cycle arrest 
in early time point and subsequently induced apoptosis at 
later time point.
Fls downregulated the mrna 
expression of PLK1 and glU1 but 
upregulated the mrna expression of 
WEE-1 and c-Jun
Differential expression of PLK1, WEE-1, c-Jun, and GLUT 
on untreated control and FLS treated MCF-7 cell was quanti-
fied by qRT-PCR assay on the cDNA synthesized from the 
extracted RNA. The results indicated that FLS significantly 
(P,0.05) downregulated expression (.2 fold) of PLK1 
and GLUT mRNA expression in MCF-7 cell. On the other 
hand, it upregulated WEE-1 expression for all evaluated time 
points but only significantly increased c-Jun expression after 
72 hours of treatment (Figure 4).
Fls promoted the level of cDc2 
phosphorylation, Bax/Bcl-2 ratio, p53, 
active caspases, and cytochrome c
Based on the Western blot analysis, level of tumor suppres-
sor p53 and proapoptotic Bax were upregulated in time-
dependent manner. Furthermore, the level of antiapoptotic 
protein Bcl-2 was downregulated in the similar trend as 
well (Figure 5). The phosphorylation of CDC2 significantly 
increased with drastic reduction in CDC2 total protein 
levels at 24, 48, and 72 hours. Similarly, level of activated 
caspase 9 and cytochrome c were also detected to be signifi-
cantly increased in FLS treated MCF-7 in time-dependent 
manner (Figure 6).
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Figure 2 light microscopic images of McF-7.
Notes: (A) Untreated (control) and (B) Fls treated (36 μM at 72 hours). scanning electron microscopy images of McF-7 (C) untreated (control) and (D) Fls treated (36 μM at 
72 hours). acridine orange/propidium iodide (aO/Pi) double staining of McF-7 (E) untreated (control) and (F) Fls treated (36 μM at 72 hours) and (G) Bar chart analysis of the 
percentage of viable, apoptotic and necrotic McF-7 of untreated (control) and Fls treated (36 μM at 72 hours) via aO/Pi qualitative analysis at each time point. The experiments were 
done in triplicate and all data are expressed as mean ± se with (*P,0.05). Figures shown were representative of at least three independent replicates with similar parameters.
Abbreviations: Fls: (e)-1-(2′-hydroxy-4′,6′-dimethoxyphenyl)-3-(4-methylthio)phenyl)prop-2-ene-1-one; se, standard error of the mean.
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Discussion
Fighting cancer by combining knowledge of phytochem-
istry and synthetic chemistry has been utilized to discover 
potential chemotherapy agents with better selectivity against 
cancer than normal cell.7 Phytochemicals isolated from the 
natural sources have been proven with multiple bioactivities 
including anticancer activity but at the same time facing 
disadvantages such as lack of accessibility, and not being cost 
or time effective to obtain in large volume. These shortages 
can be overcome by synthetic compounds and even modi-
fied to increase the availability, bioactivities, and selectivity 
against cancer cell.14
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Figure 3 Flow cytometry cell cycle and annexin V analyses of control and Fls treated McF-7 cells. 
Notes: (A) histogram analysis of cell cycle and (B) bar chart showing the percentage of cell in each phase of the cell cycle in McF-7 for 24, 48, and 72 hours when treated 
with ic50 dose of Fls (36 μM). (C) histogram analysis of annexin V/FiTc and (D) bar chart showing the percentage of cell stained with FiTc and Pi in McF-7 treated 
with ic50 dose of Fls (36 μM) for 24, 48, and 72 hours. The experiments were done in triplicate and all data are expressed as mean ± se with (*P,0.05). sub-g0/g1 is 
sub-gap0/gap1 phase. ic50 represents the concentration of Fls reduced 50% of McF-7 cells viability.
Abbreviations: Fls: (e)-1-(2′-hydroxy-4′,6′-dimethoxyphenyl)-3-(4-methylthio)phenyl)prop-2-ene-1-one; se, standard error of the mean; FiTc+/Pi+, late apoptosis 
population; FiTc−/Pi−, healthy cell population; FiTc+/Pi−, early apoptosis population; S, synthesis; RFU, relative fluorescence unit.
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Abbreviations: Fls: (e)-1-(2′-hydroxy-4′,6′-dimethoxyphenyl)-3-(4-methylthio)phenyl)prop-2-ene-1-one; se, standard error of the mean; qPcr, quantitative real time 
polymerase chain reaction.
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Figure 5 Differential protein expression of untreated and Fls treated McF-7 cells.
Notes: (A) Western blot analysis of cell cycle and apoptotic-related proteins; cDc2, p-cDc2, BaX, Bcl-2, and p53 in McF-7 treated with Fls (36 μM) for 24, 48, and 72 
hours. Bar chart analysis of related proteins (B) cDc2 and p-cDc2, (C) ratio of BaX/Bcl-2 and (D) p53 after normalized against beta actin (acTB). The experiment was 
done in triplicate and the data are expressed as mean ± se with (*P,0.05). White bars with black dots is cDc2 while black bars with white dots is p-cDc2.
Abbreviations: Fls: (e)-1-(2′-hydroxy-4′,6′-dimethoxyphenyl)-3-(4-methylthio)phenyl)prop-2-ene-1-one; se, standard error of the mean.
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Figure 6 Detection of the activation of caspase 9 and cytochrome c in McF-7 
treated with Fls (36 μM) for 24, 48, and 72 hours.
Note: The experiment was done in triplicate and the data are expressed as mean ± 
se with (*P,0.05).
Abbreviations: Fls: (e)-1-(2′-hydroxy-4′,6′-dimethoxyphenyl)-3-(4-methylthio)
phenyl)prop-2-ene-1-one; se, standard error of the mean.
Several studies have shown that chalcone is an important 
class for the anticancer properties against various cancer cell 
lines.14 Previously, we have synthesized FLA and FLB and 
investigated their cytotoxic effects antimetastatic effects on 
MCF-7 and MDA-MB-231 breast cancer cell lines in vivo and 
in vitro.9,10 In terms of FLA9 and FLB (Abu et al),10 they pos-
sessed greater selectivity against MDA-MB-231 (SI: 5.72 for 
FLA and 3.66 for FLB) than MCF-7 (SI: 3.98 for FLA and 
1.33 for FLB) with IC
50
 on normal MCF-10A around 100 
and 45 μM for FLA and FLB, respectively. Although FLA 
and FLB showed good cytotoxicity against MDA-MB-231 
cell, their effect on MCF-7 was just marginal with poor SI 
especially FLB, which has lower IC
50
 value on normal breast 
cell line. In this study, flavokawain derivative (FLS) was syn-
thesized and subjected to cytotoxicity evaluation. MTT assay 
indicated that synthetic FLS was more sensitive to MCF-7 than 
MDA-MB-231 compared to FLA and FLB (Table 1). More 
interestingly, FLS did not show IC
50
 value (.180) on normal 
breast MCF-10A cell thus giving the SI of 5.4 to MCF-10A/
MCF-7. However, the SI of FLS against MCF-10A/MDA-
MB-231 was lower than FLS against MCF-10A/MFC-7 since 
its cytotoxicity against MDA-MB-231 was low (Table 1). 
Chalcones consist of two aromatic rings (A and B) linked by a 
three-carbon unit αβ-unsaturated carbonyl moiety, which acts 
as a Michael acceptor. Apart from various substitutions on two 
rings, basic skeleton of chalcone (1,3-diphenyl-2-propenone) 
is potential in the treatment of human breast cancer.1,15–17 The 
difference in the structure of the compounds is the presence 
of methoxy (OCH
3
) in FLA and SCH
3
 (thiomethyl group) in 
FLS, meanwhile no substituent is present on ring B of FLB. 
The presence of SCH
3
 and OCH
3
 on ring B showed the 
contribution against maintaining cytotoxicity on MCF-7 cell 
but less toxic toward normal MCF-10A cell, which possibly due 
to the involvement of electron donating group, makes enrich 
scaffold αβ-unsaturated carbonyl moiety to further promote 
apoptosis in breast cancer MCF-7 cells but without further 
affecting of normal breast MCF-10A cells. Previous report 
by Ethiraj et al18 has shown that electron donating groups in 
chalcones have reduced the cytotoxic activity against cancer 
cell. FLB, free of electron donating methoxy or thiomethyl 
group, was found to be more sensitive to both breast cancer 
MDA-MB-231 and normal MCF-10A cell lines comparing 
to both FLA and FLS (Table 1). On the other hand, FLS and 
FLA with electron donating group possessed the advantage 
of less toxic in breast normal MCF-10A cell thus improved 
the selectivity against breast cancer.
Since FLS showed better cytotoxic potential against 
MCF-7 cell, the mode of cell death and cell cycle arrest 
induced and cell cycle arrest effects were evaluated on 
MCF-7 using IC
50
 value of FLS at 48 hours (36 μM). As 
indicated by the light microscope observation, reduction 
of cell number was recorded in FLS treated MCF-7 cell 
(Figure 2B). This result was further supported by the cell 
cycle analysis where G2/M arrest was observed as early as 
24 hours post-FLS treatment. This effect might be contributed 
by the significant upregulation and downregulation of WEE-1 
and PLK-1 in the treated cell, respectively (Figure 4). PLK1, 
a mitotic polo-like kinase, is a key regulator of G2/M phase 
progression while WEE-1 is the nuclear kinase that inhibits 
the entry of cell into mitosis.19 Overexpression of PLK1 is 
always reported in different types of cancer including breast 
cancer, while downregulation of PLK1 was found to link with 
G2/M arrest and subsequently apoptosis posttreatment with 
natural compound such as FLA.9 Cell cycle kinase subunit 
(CDC2) that binds to cyclin B1 to regulate progression from 
G2 to M transition was also found to be downregulated by 
FLS. FLS suggests that the downregulation of CDC2 protein 
level contributes to the increase of CDC2 phosphorylation. 
Suppression of PLK1 and upregulation of WEE-1 were 
reported to contribute to the downregulation of CDC2 via 
CDC2 Tyrosine-15 phosphorylation.20 Concomitant with 
this, similar trend was observed in FLS treated MCF-7 
cell. Cyclin-dependent kinase inhibitor p21, which can be 
upregulated by p53, was promoted in FLA and FLB treated 
MCF-7 cell.9,10 In terms of FLS treated MCF-7 cell, although 
p53 was found to be upregulated (Figure 5), its role in the 
regulation of G2/M may be marginal because p21 was not 
significantly upregulated when evaluated using qRT-PCR 
(results not shown). Previous study has shown that G2/M 
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arrest can occur with or without the involvement of tumor 
suppressor p53. Although the regulation of p21 in MCF-7 
treated with FLS was difference comparing to FLA and FLB, 
all of these compounds were found to promote G2/M arrest 
via deregulation of PLK1.9,10,19
Apoptosis was significantly (P,0.05) enhanced in MCF-7 
after 48 and 72 hours of FLS treatment in Annexin V/PI 
apoptosis study. The result was further supported by the mor-
phology observations where FLS treated MCF-7 was found 
with typical characteristic of apoptosis including cell detach, 
cell shrinkage, membrane blebbing, hole, apoptotic body, and 
chromatin condensation (Figure 2). FLS modulated apoptosis 
via upregulation of p53, Bax, caspase 9, and cytochrome c. 
FLS induced DNA damage associated with tumor suppres-
sor p53 upregulation. p53 was reported as a key regulator of 
BCL family where its upregulation was found to promote 
proapoptotic BAX and suppress antiapoptotic Bcl-2, which 
led to secretion of cytochrome c that stimulates the caspase 
cascade activation of cell death.21 Study has shown that mito-
chondria played a factor in the initiation of apoptotic process 
by releasing cytochrome c, apoptogenic factor from the outer 
mitochondria membrane space into cytosol of the apoptotic 
cells.22 Concomitant with this, upon cytochrome c leakage, 
caspase 9 was being activated. This suggests that FLS induced 
changes in the mitochondrial membrane potential in the early 
stages of apoptotic cell death via mitochondrial-dependent 
intrinsic pathway. In this study, raised BAX/Bcl-2 ratio, cyto-
chrome c, and caspase 9 in the FLS treated MCF-7 indicated 
the involvement of FLS in promoting the intrinsic apoptosis 
as detected in flow cytometry and microscopic examinations. 
Our previous reports have shown higher sensitivity of FLA 
and FLB in mutant type p53 MDA-MB-231 cell than wild-
type p53 MCF-7 cell. In this study, FLS was more potent in 
wild-type p53 MCF-7. The higher selectivity in wild-type 
p53 MCF-7 cell may be contributed by the exchange of SCH
3
 
thiomethyl group in FLS. Previous study has shown that the 
presence of thiomethyl group improved the selectivity of 
the compound toward cancer cell and maintained its cyto-
toxicity via drastic upregulation of p53 and Bax status that 
subsequently promote apoptosis in leukemia cells. Similarly, 
regulation of FLS and this thiomethyl compound on Bcl-2 
was marginal after 24 and 48 hours treatment.23
This study reveals that FLS showed good selectivity 
against breast cancer MCF-7 than normal MCF-10A cell line. 
The cytotoxicity of FLS on MCF-7 was mainly contributed 
by G2/M cell cycle arrest and induction of apoptosis. Down-
regulation of PLK1 and upregulation of WEE-1 associated 
with phosphorylation of CDC2 were the major regulators 
of the G2/M arrest. On the other hand, mitochondrial p53 
pathway was found as the contributor of the FLS induced 
apoptosis in MCF-7 cell. The presence of SCH
3
 (thiomethyl 
group) on ring B structure might play a role in cytotoxicity 
and apoptosis of MCF-7 cell compared to other chalcones, 
FLA and FLB. Thus, FLS is more potent candidate in selec-
tively combating MCF-7 breast cancer cell. Further in vivo 
study shall be carried out to evaluate the antibreast cancer 
efficacy of FLS comparing to FLA and FLB.
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